APA (7th ed.) Citation

JT, D., R, Z., H, S., JF, K., JK, T., JS, W., . . . A, A. (2025). Cognitive impairment in patients with melanoma before adjuvant immune checkpoint inhibitor therapy and associations with brain gray matter, catechol-O-methyltransferase genotype, and psychological factors. Cancer, 131(2), e35683. https://doi.org/10.1002/cncr.35683

Chicago Style (17th ed.) Citation

JT, Danielsen, Zachariae R, Schmidt H, Kallehauge JF, Thomadsen JK, Wefel JS, Wu LM, and Amidi A. "Cognitive Impairment in Patients with Melanoma Before Adjuvant Immune Checkpoint Inhibitor Therapy and Associations with Brain Gray Matter, Catechol-O-methyltransferase Genotype, and Psychological Factors." Cancer 131, no. 2 (2025): e35683. https://doi.org/10.1002/cncr.35683.

MLA (9th ed.) Citation

JT, Danielsen, et al. "Cognitive Impairment in Patients with Melanoma Before Adjuvant Immune Checkpoint Inhibitor Therapy and Associations with Brain Gray Matter, Catechol-O-methyltransferase Genotype, and Psychological Factors." Cancer, vol. 131, no. 2, 2025, p. e35683, https://doi.org/10.1002/cncr.35683.